Company / Cash & Equivalents
Ovid Therapeutics Inc. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$13.2M
FY2025
5-year range
$13.2M / $44.9M
FY2022-FY2025
Trend
-50.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 3 consecutive years, from $45M in FY2022 to $13M in FY2025.
Based on SEC 10-K filings.
$13M in FY2025 with a 3-year CAGR of -33.6%.
Declined from $27M to $13M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -33.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Ovid Therapeutics Inc.'s cash & equivalents has declined for 3 consecutive years.
- 3-year CAGR of -33.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 50.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.2M | -50.0% |
| FY2024 | $26.3M | -2.7% |
| FY2023 | $27.0M | -39.7% |
| FY2022 | $44.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026